russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2024-6074RVMZQErussjcardiol-6074Research ArticleСОГЛАШЕНИЕ ЭКСПЕРТОВEXPERT CONSENSUSКонцепция применения комбинированных препаратов с фиксированными дозировками в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Меморандум экспертов Российского кардиологического общества, Российского общества профилактики неинфекционных заболеваний, Российского научного медицинского общества терапевтов, Российской ассоциации эндокринологов, Ассоциации клинических фармакологов, Евразийской ассоциации терапевтов, Российской ассоциации геронтологов и гериатровThe concept of fixed-dose combination drugs in primary and secondary prevention of cardiovascular disease. Position paper of the Russian Society of Cardiology, the Russian Society for the Prevention of Noncommunicable Diseases, the Russian Scientific Medical Society of Internal Medicine, the Russian Association of Endocrinologists, the Association of Clinical Pharmacologists, the Eurasian Association of Internal Medicine, the Russian Association of Gerontologists and Geriatricianshttps://orcid.org/0000-0002-6645-2515АрутюновГ. П.ArutyunovG. P.

Арутюнов Григорий Павлович — д.м.н., профессор, член-корр. РАН, заслуженный врач РФ, зав. кафедрой пропедевтики внутренних болезней педиатрического факультета 

Москва

arut@ossn.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна — профессор, д.м.н., академик РАН, директор

Москва

drapkina@bk.ruhttps://orcid.org/0000-0002-5873-1768КобалаваЖ. Д.KobalavaZh. D.

Кобалава Жанна Давидовна — д.м.н., профессор, член-корр. РАН, зав. кафедрой внутренних болезней с курсом кардиологии и функциональной диагностики, зав. кафедрой внутренних болезней, кардиологии и клинической фармакологии

Москва

zkobalava@mail.ruhttps://orcid.org/0000-0001-8169-7812КонрадиА. О.KonradiA. O.

Конради Александра Олеговна — д.м.н., профессор, академик РАН, зам. генерального директора по научной работе 

Санкт-Петербург

konradi@almazovcentre.ruhttps://orcid.org/0000-0003-1943-1137ЛопатинЮ. М.LopatinYu. M.

Лопатин Юрий Михайлович — д.м.н., профессор, член-корр. РАН, зав. кафедрой кардиологии, сердечно-сосудистой и торакальной хирургии ИНМФО ФГБОУ ВО "ВолгГМУ" Минздрава России, зав. первым кардиологическим отделением ГБУЗ "Волгоградский областной клинический кардиологический центр"

Волгоград

prof_lopatin@mail.ruhttps://orcid.org/0000-0001-5981-1754НедогодаС. В.NedogodaS. V.

Недогода Сергей Владимирович — д.м.н., профессор, зав. кафедрой внутренних болезней ИНМФО 

Волгоград

vb-inmfo@yandex.ruhttps://orcid.org/0000-0002-4496-3680СычевД. А.SychevD. A.

Сычев Дмитрий Алексеевич — д.м.н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии 

Москва

dmitry.alex.sychev@mail.ruhttps://orcid.org/0000-0002-4193-688XТкачеваО. Н.TkachevaO. N.

Ткачева Ольга Николаевна — д.м.н., профессор, член-корр. РАН, директор

Москва

tkacheva@rgnkc.ruhttps://orcid.org/0000-0003-3893-9972ШестаковаМ. В.ShestakovaM. V.

Шестакова Марина Владимировна — д.м.н., профессор, академик РАН, зам. директора НМИЦ эндокринологии, директор Института Диабета

Москва

shestakova.mv@gmail.comhttps://orcid.org/0000-0003-2929-0980ШляхтоЕ. В.ShlyakhtoE. V.

Шляхто Евгений Владимирович — д.м.н., профессор, академик РАН, Президент Российского кардиологического общества (РКО), директор 

Санкт-Петербург

e.shlyakhto@almazovcentre.ruhttps://orcid.org/0000-0001-6654-1000БолотоваС. Л.BolotovaS. L.

К.м.н., доцент кафедры внутренних болезней ИНМФО ФГБОУ ВО "ВолгГМУ" Минздрава России

Волгоград

https://orcid.org/0000-0001-7652-2962ВиллевальдеС. В.VillevaldeS. V.

Д.м.н., профессор, начальник службы анализа и перспективного планирования управления по реализации федеральных проектов, зав. кафедрой кардиологии

Санкт-Петербург

https://orcid.org/0000-0002-4510-6197ГалявичА. С.GalyavichA. S.

Д.м.н., профессор, зав. кафедрой кардиологии ФПК и ППС 

Казань

https://orcid.org/0000-0002-1518-6552ЕжовМ. В.EzhovM. V.

Д.м.н., Президент Национального Общества по изучению Атеросклероза (НОА), г.н.с. отдела проблем атеросклероза, руководитель лаборатории нарушений липидного обмена

Москва

https://orcid.org/0000-0003-1480-0458КарповЮ. А.KarpovYu. A.

Д.м.н., профессор, г.н.с.

Москва

https://orcid.org/0000-0001-7003-5186КозиоловаН. А.KoziolovaN. A.

Д.м.н., профессор, зав. кафедрой пропедевтики внутренних болезней № 2 

Пермь

https://orcid.org/0000-0003-2062-1536КонцеваяА. В.KontsevayaA. V.

Д.м.н., профессор, зам. директора по научной и аналитической работе, руководитель лаборатории социально-экономического анализа риска хронических неинфекционных заболеваний 

Москва

https://orcid.org/0000-0002-1628-5093КотовскаяВ. В.KotovskayaYu. V.

Д.м.н., профессор, зам. директора по научной работе 

Москва

https://orcid.org/0000-0001-8892-6411НедошивинА. О.NedoshivinA. O.

Д.м.н., профессор, Генеральный секретарь РКО, ученый секретарь, профессор кафедры факультетской терапии с клиникой лечебного факультета Института медицинского образования

Санкт-Петербург

https://orcid.org/0000-0002-0795-8225ОстроумоваО. Д.OstroumovaO. D.

Д.м.н., профессор, зав. кафедрой терапии и полиморбидной патологии им. акад. М. С. Вовси 

Москва

https://orcid.org/0000-0001-5680-4663ПолунинаН. А.PoluninaN. A.

К.м.н., доцент кафедры фундаментальной нейрохирургии ФДПО "РНИМУ им. Н. И. Пирогова", н.с. отделения неотложной нейрохирургии НИИ СП им. Н. В. Склифосовского, врач-нейрохирург Московского Многопрофильного Клинического Центра "Коммунарка" ДЗМ

Москва

https://orcid.org/0000-0002-6611-9165СаласюкА. С.SalasyukA. S.

Д.м.н., профессор кафедры внутренних болезней ИНМФО 

Волгоград

salasyukas@outlook.comhttps://orcid.org/0000-0002-4855-418XСкибицкийВ. В.SkibitskyV. V.

Д.м.н., профессор, зав. кафедрой госпитальной терапии

Краснодар

https://orcid.org/0000-0002-9659-7010ТарловскаяЕ. И.TarlovskayaE. I.

Д.м.н., профессор, зав. кафедрой терапии и кардиологии 

Нижний Новгород

https://orcid.org/0000-0003-1756-7583ТроицкаяЕ. А.TroitskayaE. A.

К.м.н., доцент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики им. акад. В. С. Моисеева

Москва

https://orcid.org/0000-0002-9323-592XЧесниковаА. И.ChesnikovaA. I.

Д.м.н., профессор, профессор кафедры внутренних болезней № 1 

Ростов-на-Дону

https://orcid.org/0000-0002-0389-560XФроловМ. Ю.FrolovM. Yu.

К.м.н., доцент кафедры фармакологии и фармации ИНМФО ФГБОУ ВО "ВГМУ" Минздрава России, зав. отделом фармакологии ГБУ "Волгоградский медицинский научный центр"

Волгоград

ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава РоссииRussian FederationФГБУ «НМИЦ ТПМ» Минздрава РоссииRussian FederationМедицинский институт РУДНRussian FederationФГБУ Национальный медицинский исследовательский центр им. В. А. Алмазова Минздрава РоссииRussian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России; ГБУЗ «Волгоградский областной клинический кардиологический центр»Russian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииRussian FederationОСП «Российский геронтологический научно-клинический центр» ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России,Russian FederationНациональный медицинский исследовательский центр эндокринологииRussian FederationФГБУ НИМЦ им. В. А. Алмазова Минздрава РоссииRussian FederationИНМФО ФГБОУ ВО "ВолгГМУ" Минздрава РоссииRussian FederationФГБУ "НИМЦ им. В. А. Алмазова" Минздрава РоссииRussian FederationФГБОУ ВО "Казанский государственный медицинский университет"Russian FederationФГБУ "НМИЦ кардиологии им. акад. Е. И. Чазова" Минздрава РоссииRussian FederationФГБОУ ВО "Пермский государственный медицинский университет им. акад. Е. А. Вагнера"Russian FederationФГБУ "НМИЦ терапии и профилактической медицины" Минздрава РоссииRussian FederationОСП "Российский геронтологический научно-клинический центр" ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава РоссииRussian FederationФГБУ "НМИЦ им. В. А. Алмазова" Минздрава РоссииRussian FederationФГБОУ ДПО "РМАНПО" Минздрава РоссииRussian FederationФДПО "РНИМУ им. Н. И. Пирогова"; НИИ СП им. Н. В. Склифосовского; Московский Многопрофильный Клинический Центр "Коммунарка" ДЗМRussian FederationФГБОУ ВО "ВолгГМУ", Минздрава РоссииRussian FederationФГБОУ ВО "КГМУ" Минздрава РоссииRussian FederationФГБОУ ВО "НГМА"Russian FederationФГБОУ ВО "Ростовский государственный медицинский университет" Минздрава РоссииRussian FederationФГБОУ ВО "ВГМУ" Минздрава России; ГБУ "Волгоградский медицинский научный центр"Russian Federation20241208202429960746074Copyright © Арутюнов Г.П., Драпкина О.М., Кобалава Ж.Д., Конради А.О., Лопатин Ю.М., Недогода С.В., Сычев Д.А., Ткачева О.Н., Шестакова М.В., Шляхто Е.В., Болотова С.Л., Виллевальде С.В., Галявич А.С., Ежов М.В., Карпов Ю.А., Козиолова Н.А., Концевая А.В., Котовская В.В., Недошивин А.О., Остроумова О.Д., Полунина Н.А., Саласюк А.С., Скибицкий В.В., Тарловская Е.И., Троицкая Е.А., Чесникова А.И., Фролов М.Ю., 20242024Арутюнов Г.П., Драпкина О.М., Кобалава Ж.Д., Конради А.О., Лопатин Ю.М., Недогода С.В., Сычев Д.А., Ткачева О.Н., Шестакова М.В., Шляхто Е.В., Болотова С.Л., Виллевальде С.В., Галявич А.С., Ежов М.В., Карпов Ю.А., Козиолова Н.А., Концевая А.В., Котовская В.В., Недошивин А.О., Остроумова О.Д., Полунина Н.А., Саласюк А.С., Скибицкий В.В., Тарловская Е.И., Троицкая Е.А., Чесникова А.И., Фролов М.Ю.Arutyunov G.P., Drapkina O.M., Kobalava Z.D., Konradi A.O., Lopatin Y.M., Nedogoda S.V., Sychev D.A., Tkacheva O.N., Shestakova M.V., Shlyakhto E.V., Bolotova S.L., Villevalde S.V., Galyavich A.S., Ezhov M.V., Karpov Y.A., Koziolova N.A., Kontsevaya A.V., Kotovskaya Y.V., Nedoshivin A.O., Ostroumova O.D., Polunina N.A., Salasyuk A.S., Skibitsky V.V., Tarlovskaya E.I., Troitskaya E.A., Chesnikova A.I., Frolov M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/6074

В меморандуме представлена позиция Совета Экспертов Российского кардиологического общества (РКО), Российского общества профилактики неинфекционных заболеваний (РОПНИЗ), Российского научного медицинского общества терапевтов (РНМОТ), Российской ассоциации эндокринологов (РАЭ), Ассоциации клинических фармакологов (АКФ), Евразийской ассоциации терапевтов (ЕАТ), Российской ассоциации геронтологов и гериатров (РАГГ) по наиболее важным и дискуссионным вопросам применения комбинированных препаратов с фиксированными дозировками в первичной и вторичной профилактике сердечно-сосудистых заболеваний.

The paper describes the position of of the Russian Society of Cardiology, the Russian Society for the Prevention of Noncommunicable Diseases, the Russian Scientific Medical Society of Internal Medicine, the Russian Association of Endocrinologists, the Association of Clinical Pharmacologists, the Eurasian Association of Internal Medicine, the Russian Association of Gerontologists and Geriatricians on the most important and controversial issues of the use of fixed-dose combination drugs in the primary and secondary prevention of cardiovascular disease.

политаблеткафиксированные комбинациисердечно-сосудистая профилактикасердечно-сосудистый рискартериальная гипертензиядислипидемияишемическая болезнь сердцахроническая сердечная недостаточностьсахарный диабетpolypillfixed-dose combinationscardiovascular preventioncardiovascular riskhypertensiondyslipidemiacoronary artery diseaseheart failurediabetesReferencesКобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.Borghi C, Wang J, Rodionov AV, et al. Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries. Int J Cardiol Cardiovasc Risk Prev. 2021;10:200102. doi:10.1016/j.ijcrp.2021.200102.Borghi C, Wang J, Rodionov AV, et al. Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries. Int J Cardiol Cardiovasc Risk Prev. 2021;10:200102. doi:10.1016/j.ijcrp.2021.200102.Webster R, Castellano JM, Onuma OK. Putting polypills into practice: challenges and lessons learned. Lancet. 2017;389(10073):1066-74. doi:10.1016/S0140-6736(17)30558-5.Webster R, Castellano JM, Onuma OK. Putting polypills into practice: challenges and lessons learned. Lancet. 2017;389(10073):1066-74. doi:10.1016/S0140-6736(17)30558-5.Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419. doi:10.1136/bmj.326.7404.1419.Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419. doi:10.1136/bmj.326.7404.1419.Sarfo FS, Nichols M, Opare-Addo PA, Ovbiagele B.Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation. Stroke. 2023;54(2):407-14. doi:10.1161/STROKEAHA.122.039567.Sarfo FS, Nichols M, Opare-Addo PA, Ovbiagele B.Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation. Stroke. 2023;54(2):407-14. doi:10.1161/STROKEAHA.122.039567.Yusuf S, Pinto FJ. The polypill: from concept and evidence to implementation. Lancet. 2022;400(10364):1661-3. doi:10.1016/S0140-6736(22)01847-5.Yusuf S, Pinto FJ. The polypill: from concept and evidence to implementation. Lancet. 2022;400(10364):1661-3. doi:10.1016/S0140-6736(22)01847-5.Vijay K, Prasad B, Singh S.Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discovery Today: Therapeutic Strategies. 2008;5(1):63-71. doi:10.1016/j.ddstr.2008.03.001.Vijay K, Prasad B, Singh S.Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discovery Today: Therapeutic Strategies. 2008;5(1):63-71. doi:10.1016/j.ddstr.2008.03.001.Ibanez B, James S, Agewall S, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.Ibanez B, James S, Agewall S, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.Visseren FLJ, Mach F, Smulders YM, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429. English, Spanish. doi:10.1016/j.rec.2022.04.003.Visseren FLJ, Mach F, Smulders YM, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429. English, Spanish. doi:10.1016/j.rec.2022.04.003.Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281-344. doi:10.1016/j.atherosclerosis.2016.08.018.Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281-344. doi:10.1016/j.atherosclerosis.2016.08.018.Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30(3):427-32; discussion 433-4. doi:10.1093/ije/30.3.427.Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30(3):427-32; discussion 433-4. doi:10.1093/ije/30.3.427.Fuster V, Sanz G. Compuestos de dosis fija en la prevención secundaria de la cardiopatía isquémica [Fixed-dose compounds and the secondary prevention of ischemic heart disease]. Rev Esp Cardiol. 2011;64 Suppl 2:3-9. Spanish. doi:10.1016/j.recesp.2011.02.027.Fuster V, Sanz G. Compuestos de dosis fija en la prevención secundaria de la cardiopatía isquémica [Fixed-dose compounds and the secondary prevention of ischemic heart disease]. Rev Esp Cardiol. 2011;64 Suppl 2:3-9. Spanish. doi:10.1016/j.recesp.2011.02.027.Yusuf S, Joseph P, Dans A, et al.; International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216-28. doi:10.1056/NEJMoa2028220.Yusuf S, Joseph P, Dans A, et al.; International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216-28. doi:10.1056/NEJMoa2028220.Yusuf S, Lonn E, Pais P, et al.; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2032- 43. doi:10.1056/NEJMoa1600177.Yusuf S, Lonn E, Pais P, et al.; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2032- 43. doi:10.1056/NEJMoa1600177.Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, clusterrandomised trial. Lancet. 2019;394(10199):672-83. doi:10.1016/S0140-6736(19)31791-X.Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, clusterrandomised trial. Lancet. 2019;394(10199):672-83. doi:10.1016/S0140-6736(19)31791-X.Jahangiri R, Rezapour A, Malekzadeh R, et al. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review. PLoS One. 2022;17(7):e0271908. doi:10.1371/journal.pone.0271908.Jahangiri R, Rezapour A, Malekzadeh R, et al. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review. PLoS One. 2022;17(7):e0271908. doi:10.1371/journal.pone.0271908.Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-98. doi:10.1056/NEJMsa053935.Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-98. doi:10.1056/NEJMsa053935.Kotseva K, Wood D, De Backer G, et al.; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37. doi:10.1097/HJR.0b013e3283294b1d.Kotseva K, Wood D, De Backer G, et al.; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37. doi:10.1097/HJR.0b013e3283294b1d.Шальнова С.А., Деев А.Д., Метельская В.А. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2016;15(4):29-37. doi:10.15829/1728-8800-2016-4-29-37.Shalnova SA, Deev AD, Metelskaya VA, et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Cardiovascular Therapy and Prevention. 2016;15(4):29-37. (In Russ.) doi:10.15829/1728-8800-2016-4-29-37.Sanz G, Fuster V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Mt Sinai J Med. 2012;79(6):683-8. doi:10.1002/msj.21355.Sanz G, Fuster V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Mt Sinai J Med. 2012;79(6):683-8. doi:10.1002/msj.21355.Armstrong PW, McAlister FA. Searching for Adherence: Can We Fulfill the Promise of Evidence-Based Medicines? J Am Coll Cardiol. 2016;68(8):802-4. doi:10.1016/j.jacc.2016.06.006.Armstrong PW, McAlister FA. Searching for Adherence: Can We Fulfill the Promise of Evidence-Based Medicines? J Am Coll Cardiol. 2016;68(8):802-4. doi:10.1016/j.jacc.2016.06.006.Rao S, Jamal Siddiqi T, Khan MS, et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Prog Cardiovasc Dis. 2022;73:48-55. doi:10.1016/j.pcad.2022.01.005.Rao S, Jamal Siddiqi T, Khan MS, et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Prog Cardiovasc Dis. 2022;73:48-55. doi:10.1016/j.pcad.2022.01.005.Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071-82. doi:10.1016/j.jacc.2014.08.021.Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071-82. doi:10.1016/j.jacc.2014.08.021.Hennawi HA, Ashraf MT, Zohaib M, et al. Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Curr Probl Cardiol. 2023;48(8):101735. doi:10.1016/j.cpcardiol.2023.101735.Hennawi HA, Ashraf MT, Zohaib M, et al. Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Curr Probl Cardiol. 2023;48(8):101735. doi:10.1016/j.cpcardiol.2023.101735.Yasmin F, Aamir M, Ullah W, et al. Efficacy of polypill therapy for secondary prevention of cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. JACC. 2023;81 (8_Supplement) 1840. doi:10.1016/S0735-1097(23)02284-2.Yasmin F, Aamir M, Ullah W, et al. Efficacy of polypill therapy for secondary prevention of cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. JACC. 2023;81 (8_Supplement) 1840. doi:10.1016/S0735-1097(23)02284-2.Castellano JM, Pocock SJ, Bhatt DL, et al.; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.Castellano JM, Pocock SJ, Bhatt DL, et al.; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318. doi:10.1136/bmj.g3318.Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318. doi:10.1136/bmj.g3318.Rivera A, Campos B, Ceolin S, et al. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2023;30(16):1828-37. doi:10.1093/eurjpc/zwad245.Rivera A, Campos B, Ceolin S, et al. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2023;30(16):1828-37. doi:10.1093/eurjpc/zwad245.González-Juanatey JR, Cordero A, Castellano JM, et al. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study. Int J Cardiol. 2022;361:116-23. doi:10.1016/j.ijcard.2022.05.015.González-Juanatey JR, Cordero A, Castellano JM, et al. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study. Int J Cardiol. 2022;361:116-23. doi:10.1016/j.ijcard.2022.05.015.Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.Sarzani R, Laureti G, Gezzi A, et al. Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Ther Adv Chronic Dis. 2022;13:20406223221102754. doi:10.1177/20406223221102754.Sarzani R, Laureti G, Gezzi A, et al. Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Ther Adv Chronic Dis. 2022;13:20406223221102754. doi:10.1177/20406223221102754.Coca A, Kreutz R, Manolis AJ, Mancia G. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. J Hypertens. 2020;38(10):1890-8. doi:10.1097/HJH.0000000000002464.Coca A, Kreutz R, Manolis AJ, Mancia G. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. J Hypertens. 2020;38(10):1890-8. doi:10.1097/HJH.0000000000002464.Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation. 2013;128(1):29-41. doi:10.1161/CIRCULATIONAHA.112.000500.Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation. 2013;128(1):29-41. doi:10.1161/CIRCULATIONAHA.112.000500.Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol. 1999;10 Suppl 12:S278-82.Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol. 1999;10 Suppl 12:S278-82.Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041-6. doi:10.1161/HYPERTENSIONAHA.114.05021.Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041-6. doi:10.1161/HYPERTENSIONAHA.114.05021.Ernst ME, Fravel MA. Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. Am J Hypertens. 2022;35(7):573- 86. doi:10.1093/ajh/hpac048.Ernst ME, Fravel MA. Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. Am J Hypertens. 2022;35(7):573- 86. doi:10.1093/ajh/hpac048.Grigorian-Shamagian L, Edel K, Esteve-Pastor MA, et al. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe. Front Cardiovasc Med. 2021;8:663361. doi:10.3389/fcvm.2021.663361.Grigorian-Shamagian L, Edel K, Esteve-Pastor MA, et al. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe. Front Cardiovasc Med. 2021;8:663361. doi:10.3389/fcvm.2021.663361.Рабочая группа по лечению артериальной гипертензии Европейского общества кардиологов (ЕОК, ESC) и Европейского общества по артериальной гипертензии (ЕОАГ, ESH). 2018 ЕОК/ЕОАГ Рекомендации по лечению больных с артериальной гипертензией. Российский кардиологический журнал. 2018;(12):143-228. doi:10.15829/1560-4071-2018-12-143-228.The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH Guidelines for the management of arterial hypertension. Russian Journal of Cardiology. 2018;(12):143-228. (In Russ.) doi:10.15829/1560-4071-2018-12-143-228.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme in inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97. doi:10.1001/jama.288.23.2981.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme in inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97. doi:10.1001/jama.288.23.2981.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressurelowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressurelowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.Patel A, MacMahon S, Chalmers J, Neal B, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40. doi:10.1016/S0140-6736(07)61303-8.Patel A, MacMahon S, Chalmers J, Neal B, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40. doi:10.1016/S0140-6736(07)61303-8.Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259-64. doi:10.1161/HYPERTENSIONAHA.113.02252. Erratum in: Hypertension. 2015;66(1):e2. doi:10.1161/HYP.0000000000000030.Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259-64. doi:10.1161/HYPERTENSIONAHA.113.02252. Erratum in: Hypertension. 2015;66(1):e2. doi:10.1161/HYP.0000000000000030.Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. doi:10.1016/S0140-6736(02)08089-3.Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. doi:10.1016/S0140-6736(02)08089-3.Julius S, Kjeldsen SE, Weber M, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31. doi:10.1016/S0140-6736(04)16451-9.Julius S, Kjeldsen SE, Weber M, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31. doi:10.1016/S0140-6736(04)16451-9.Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.Ogihara T, Saruta T, Rakugi H, et al.; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res. 2015;38(1):89-96. doi:10.1038/hr.2014.144.Ogihara T, Saruta T, Rakugi H, et al.; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res. 2015;38(1):89-96. doi:10.1038/hr.2014.144.Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. doi:10.1016/s0140-6736(98)05012-0.Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. doi:10.1016/s0140-6736(98)05012-0.Black HR, Elliott WJ, Grandits G, et al.; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-82. doi:10.1001/jama.289.16.2073.Black HR, Elliott WJ, Grandits G, et al.; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-82. doi:10.1001/jama.289.16.2073.Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-65. doi:10.1016/s0140-6736(00)02526-5.Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-65. doi:10.1016/s0140-6736(00)02526-5.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-16. doi:10.1001/jama.290.21.2805.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-16. doi:10.1001/jama.290.21.2805.Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145-51. doi:10.1136/bmj.293.6555.1145.Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145-51. doi:10.1136/bmj.293.6555.1145.Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-5. doi:10.1016/0140-6736(91)92589-t.Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-5. doi:10.1016/0140-6736(91)92589-t.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24(1):3-10. doi:10.1097/01.hjh.0000194119.42722.21.Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24(1):3-10. doi:10.1097/01.hjh.0000194119.42722.21.Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68. doi:10.1016/S0140-6736(15)00257-3.Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68. doi:10.1016/S0140-6736(15)00257-3.Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 29;356(9227):366-72. doi:10.1016/S0140-6736(00)02527-7.Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 29;356(9227):366-72. doi:10.1016/S0140-6736(00)02527-7.Brown MJ, Williams B, Morant SV, et al.; British Hypertension Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4(2):136-47. doi:10.1016/S2213-8587(15)00377-0.Brown MJ, Williams B, Morant SV, et al.; British Hypertension Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4(2):136-47. doi:10.1016/S2213-8587(15)00377-0.Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182.Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182.Matsuzaki M, Ogihara T, Umemoto S, et al.; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649-59. doi:10.1097/HJH.0b013e328348345d.Matsuzaki M, Ogihara T, Umemoto S, et al.; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649-59. doi:10.1097/HJH.0b013e328348345d.Российское кардиологическое общество (РКО) Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.Boden WE, Marzilli M, Crea F, et al.; Chronic Myocardial Ischemic Syndromes Task Force. Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81(5):505-14. doi:10.1016/j.jacc.2022.08.814.Boden WE, Marzilli M, Crea F, et al.; Chronic Myocardial Ischemic Syndromes Task Force. Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81(5):505-14. doi:10.1016/j.jacc.2022.08.814.Joseph P, Roshandel G, Gao P, et al.; Polypill Trialists’ Collaboration. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S0140-6736(21)01827-4.Joseph P, Roshandel G, Gao P, et al.; Polypill Trialists’ Collaboration. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S0140-6736(21)01827-4.Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015;170(6):1092-8. doi:10.1016/j.ahj.2015.08.018.Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015;170(6):1092-8. doi:10.1016/j.ahj.2015.08.018.Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens. 2020;38(6):1016-28. doi:10.1097/HJH.0000000000002381.Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens. 2020;38(6):1016-28. doi:10.1097/HJH.0000000000002381.Agarwal A, Mohanan PP, Kondal D, et al. Effect of a quality improvement intervention for acute heart failure in South India: An interrupted time series study. Int J Cardiol. 2021;329:123-9. doi:10.1016/j.ijcard.2020.12.048.Agarwal A, Mohanan PP, Kondal D, et al. Effect of a quality improvement intervention for acute heart failure in South India: An interrupted time series study. Int J Cardiol. 2021;329:123-9. doi:10.1016/j.ijcard.2020.12.048.Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1-157. doi:10.14341/DM13042.Dedov I, Shestakova M, Mayorov A, et al. Standards of Specialized Diabetes Care/Edited by Dedov II, Shestakova MV, Mayorov AYu. 11th Edition. Diabetes mellitus. 2023;26(2S):1- 157. (In Russ.) doi:10.14341/DM13042.ElSayed NA, Aleppo G, Aroda VR, et al., on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-S157. doi:10.2337/dc23-S009.ElSayed NA, Aleppo G, Aroda VR, et al., on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-S157. doi:10.2337/dc23-S009.Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86. doi:10.2337/dci22-0034.Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86. doi:10.2337/dci22-0034.Matthews DR, Paldánius PM, Proot P, et al.; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-29. doi:10.1016/S0140-6736(19)32131-2.Matthews DR, Paldánius PM, Proot P, et al.; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-29. doi:10.1016/S0140-6736(19)32131-2.Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010-2022 гг. Сахарный диабет. 2023;26(2):104-23. doi:10.14341/DM13035.Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes mellitus. 2023;26(2):104- 23. (In Russ.) doi:10.14341/DM13035.Böhm AK, Schneider U, Aberle J, Stargardt T.Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS One. 2021;16(5):e0250993. doi:10.1371/journal.pone.0250993.Böhm AK, Schneider U, Aberle J, Stargardt T.Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS One. 2021;16(5):e0250993. doi:10.1371/journal.pone.0250993.Nishimura R, Kato H, Kisanuki K, et al. Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):869-78. doi:10.1080/03007995.2018.1551192.Nishimura R, Kato H, Kisanuki K, et al. Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):869-78. doi:10.1080/03007995.2018.1551192.Lokhandwala T, Smith N, Sternhufvud C, et al. Retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203-12. doi:10.3111/13696998.2015.1109518.Lokhandwala T, Smith N, Sternhufvud C, et al. Retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203-12. doi:10.3111/13696998.2015.1109518.Williams SA, Buysman EK, Hulbert EM, et al. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40-8.Williams SA, Buysman EK, Hulbert EM, et al. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40-8.Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44(5):791-9. doi:10.1345/aph.1M426.Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44(5):791-9. doi:10.1345/aph.1M426.Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157-68. doi:10.1185/03007995.2011.570745.Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157-68. doi:10.1185/03007995.2011.570745.Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics. 2020;12(2):190. doi:10.3390/pharmaceutics12020190.Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics. 2020;12(2):190. doi:10.3390/pharmaceutics12020190.Kalra S, Das AK, Priya G, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7. doi:10.4103/jfmpc.jfmpc_843_20.Kalra S, Das AK, Priya G, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7. doi:10.4103/jfmpc.jfmpc_843_20.Masjuan J, Gállego J, Aguilera JM, et al. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurologia (Engl Ed). 2021;36(1):1-8. English, Spanish. doi:10.1016/j.nrl.2017.10.013.Masjuan J, Gállego J, Aguilera JM, et al. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurologia (Engl Ed). 2021;36(1):1-8. English, Spanish. doi:10.1016/j.nrl.2017.10.013.

The authors declare that there are no conflicts of interest present.